表观遗传机制在非小细胞肺癌靶向治疗获得性耐药中的研究进展
| Jazyk: | angličtina |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Chinese Journal of Lung Cancer |
| ISSN: | 1999-6187 1009-3419 |
| Popis: | Patients with oncogenic driver alterations of non-small cell lung cancer (NSCLC) can benefit from targeted therapy, but acquired resistance is inevitable ultimately. Epigenetic modifications, including DNA methylation, histone modifications, non-coding RNA-mediated regulate and chromatin remodeling, are important mechanisms of acquired resistance in targeted therapy of NSCLC. In recent years, studies have found that epigenetic modifications can effectively reverse drug resistance. Targeted therapy combined with epigenetic modifications may become a promising therapeutic strategy. Here, we review the progress of epigenetic mechanism in acquired resistance of targeted therapy in NSCLC, hoping to provide ideas for screening dominant population and overcoming resistance. .【中文题目：表观遗传机制在非小细胞肺癌靶向治疗 获得性耐药中的研究进展】 【中文摘要：驱动基因阳性的非小细胞肺癌患者能从靶向治疗中获益，但最终都不可避免地出现获得性耐药。表观遗传修饰包括DNA甲基化、组蛋白修饰、非编码RNA调控、染色质重塑等，是非小细胞肺癌靶向治疗获得性耐药的重要机制。近年来，已有研究发现表观遗传修饰的改变可以有效逆转耐药性，靶向治疗联合表观调控可能成为有前景的治疗策略。本文就非小细胞肺癌靶向治疗获得性耐药后表观遗传机制的进展进行了综述，希望为筛选优势人群、克服靶向耐药提供参考和思路。 】 【中文关键词：肺肿瘤；靶向治疗；耐药机制；表观遗传】. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|